This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.
Study Type
OBSERVATIONAL
Enrollment
387
Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
Unnamed facility
Bülach, Canton of Zurich, Switzerland
Intraocular Pressure (IOP) at Baseline
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eye at Baseline.
Time frame: Baseline
Intraocular Pressure (IOP) at Week 12
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eye at the Final Visit at approximately Week 12. The lower the IOP values the greater the improvement.
Time frame: Week 12
Physician Evaluation of Efficacy Using a 5-Point Scale
The physician evaluated efficacy using a 5-point scale (IOP lower than the target, Target IOP reached, IOP decreased but target not reached, IOP increased or No change). The number of participants in each category is reported.
Time frame: Week 12
Patient Evaluation of Tolerability of Treatment Using a 4-Point Scale
Patients evaluated their tolerability of treatment using a 4-point scale (very good, good, moderate, and poor). The number of participants in each category is reported.
Time frame: Week 12
Physician Evaluation of Tolerability of Treatment
The physician evaluated the patient's tolerability of treatment using a 4-point scale (very good, good, moderate, and poor). The percentage of participants assessed in each category is reported.
Time frame: Week 12
Physician Reported Reasons for Early Discontinuation of Treatment
The number of patients who discontinued from treatment by category is reported. More than one reason may apply to each patient.
Time frame: 12 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Patients Continuing Treatment After 12 Weeks
The number of patients continuing treatment after 12 weeks was determined by the physician answering yes to the question: Is the patient continuing on Lumigan® 0.01% treatment?
Time frame: Week 12